[go: up one dir, main page]

PL3564378T3 - Kompozycja immunogenna - Google Patents

Kompozycja immunogenna

Info

Publication number
PL3564378T3
PL3564378T3 PL19179871.9T PL19179871T PL3564378T3 PL 3564378 T3 PL3564378 T3 PL 3564378T3 PL 19179871 T PL19179871 T PL 19179871T PL 3564378 T3 PL3564378 T3 PL 3564378T3
Authority
PL
Poland
Prior art keywords
immunogenic composition
immunogenic
composition
Prior art date
Application number
PL19179871.9T
Other languages
English (en)
Inventor
Cindy Castado
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46168484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3564378(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of PL3564378T3 publication Critical patent/PL3564378T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19179871.9T 2011-05-27 2012-05-25 Kompozycja immunogenna PL3564378T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490707P 2011-05-27 2011-05-27
US201161490734P 2011-05-27 2011-05-27
US201161490716P 2011-05-27 2011-05-27

Publications (1)

Publication Number Publication Date
PL3564378T3 true PL3564378T3 (pl) 2024-03-11

Family

ID=46168484

Family Applications (4)

Application Number Title Priority Date Filing Date
PL19179871.9T PL3564378T3 (pl) 2011-05-27 2012-05-25 Kompozycja immunogenna
PL12726374T PL2714911T3 (pl) 2011-05-27 2012-05-25 Kompozycja immunogenna
PL16193340T PL3138916T3 (pl) 2011-05-27 2012-05-25 Kompozycja immunogenna
PL12724950T PL2714910T3 (pl) 2011-05-27 2012-05-25 Kompozycja immunogenna

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL12726374T PL2714911T3 (pl) 2011-05-27 2012-05-25 Kompozycja immunogenna
PL16193340T PL3138916T3 (pl) 2011-05-27 2012-05-25 Kompozycja immunogenna
PL12724950T PL2714910T3 (pl) 2011-05-27 2012-05-25 Kompozycja immunogenna

Country Status (25)

Country Link
US (5) US9290565B2 (pl)
EP (6) EP3564378B1 (pl)
JP (3) JP5952390B2 (pl)
KR (1) KR102014502B1 (pl)
CN (3) CN103732750A (pl)
BR (2) BR112013030395B1 (pl)
CA (2) CA2837393A1 (pl)
CY (3) CY1118599T1 (pl)
DK (4) DK2714910T3 (pl)
EA (1) EA030898B1 (pl)
ES (4) ES2615737T3 (pl)
FI (1) FI3564378T3 (pl)
HR (4) HRP20180339T1 (pl)
HU (4) HUE030823T2 (pl)
IL (1) IL229529B2 (pl)
LT (4) LT2714911T (pl)
ME (1) ME02600B (pl)
MX (1) MX346200B (pl)
PL (4) PL3564378T3 (pl)
PT (4) PT2714910T (pl)
RS (1) RS55605B1 (pl)
SG (1) SG195037A1 (pl)
SI (4) SI3138916T1 (pl)
SM (2) SMT201700110T1 (pl)
WO (3) WO2012163810A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3167899B1 (en) 2010-09-03 2021-03-24 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof
MX391236B (es) 2011-04-22 2025-03-21 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
SG11201402375VA (en) 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
AU2013354186A1 (en) * 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
CA2910200A1 (en) * 2013-04-22 2014-10-30 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
ES2870506T3 (es) 2015-02-19 2021-10-27 Immune Biosolutions Inc Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos
EP3810163A1 (en) * 2018-06-19 2021-04-28 GlaxoSmithKline Biologicals SA Immunogenic composition
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
DE69535530D1 (de) * 1994-10-24 2007-08-16 Ophidian Pharm Inc Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten
ATE195878T1 (de) * 1995-07-07 2000-09-15 Oravax Inc Toxine und toxoide von clostridium difficile als schleimhautadjuvans
WO2000061762A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE)
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ, インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンaタンパク質キャリア
WO2001073030A2 (en) 2000-03-28 2001-10-04 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
CA2733425A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
WO2011060431A2 (en) 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
EP3167899B1 (en) 2010-09-03 2021-03-24 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens

Also Published As

Publication number Publication date
BR112013030395B1 (pt) 2022-11-01
CY1121936T1 (el) 2020-10-14
EA030898B1 (ru) 2018-10-31
DK3564378T3 (da) 2024-01-08
HRP20191291T1 (hr) 2019-10-18
DK3138916T3 (da) 2019-08-26
SMT201700110T1 (it) 2017-03-08
HRP20231749T1 (hr) 2024-03-15
HUE030823T2 (en) 2017-06-28
EP4296361A2 (en) 2023-12-27
PL2714910T3 (pl) 2018-06-29
EP2714910B1 (en) 2018-01-10
HUE044772T2 (hu) 2019-11-28
EP3327126A1 (en) 2018-05-30
US20160159867A1 (en) 2016-06-09
EP2714911B1 (en) 2016-11-30
PT3138916T (pt) 2019-09-17
EP3564378A1 (en) 2019-11-06
WO2012163817A3 (en) 2013-03-21
HRP20180339T1 (hr) 2018-03-23
EP3564378B1 (en) 2023-11-01
PT2714911T (pt) 2017-02-06
US20170362309A1 (en) 2017-12-21
DK2714911T3 (en) 2017-02-27
JP2014516532A (ja) 2014-07-17
SI2714910T1 (en) 2018-04-30
EP2714911A2 (en) 2014-04-09
DK2714910T3 (en) 2018-02-05
US9409974B2 (en) 2016-08-09
PT2714910T (pt) 2018-03-09
PL3138916T3 (pl) 2019-11-29
ES2743442T3 (es) 2020-02-19
IL229529A0 (en) 2014-01-30
JP5952390B2 (ja) 2016-07-13
WO2012163811A1 (en) 2012-12-06
US20170247421A1 (en) 2017-08-31
CN107098977A (zh) 2017-08-29
BR112013030396A2 (pt) 2016-12-13
MX346200B (es) 2017-03-10
SI2714911T1 (sl) 2017-03-31
LT3138916T (lt) 2019-08-26
SG195037A1 (en) 2013-12-30
BR112013030395A2 (pt) 2016-12-13
LT2714910T (lt) 2018-03-12
SI3564378T1 (sl) 2024-02-29
LT3564378T (lt) 2024-01-25
JP2017012160A (ja) 2017-01-19
ES2968455T3 (es) 2024-05-09
HRP20170094T1 (hr) 2017-03-24
DK3564378T5 (da) 2024-09-02
ES2660468T3 (es) 2018-03-22
HUE064492T2 (hu) 2024-03-28
CY1119916T1 (el) 2018-06-27
EP4296361A3 (en) 2024-02-28
CN103717742B (zh) 2018-05-22
CN103717742A (zh) 2014-04-09
EA201391548A1 (ru) 2014-06-30
EP3138916A1 (en) 2017-03-08
WO2012163817A2 (en) 2012-12-06
ES2615737T3 (es) 2017-06-08
IL229529B2 (en) 2023-05-01
MX2013013924A (es) 2013-12-16
RS55605B1 (sr) 2017-06-30
US20140093529A1 (en) 2014-04-03
ME02600B (me) 2017-06-20
IL229529B1 (en) 2023-01-01
PT3564378T (pt) 2024-01-26
CA2837395A1 (en) 2012-12-06
CY1118599T1 (el) 2017-07-12
EP2714910A1 (en) 2014-04-09
SMT201700110B (it) 2017-03-08
CA2837393A1 (en) 2012-12-06
KR102014502B1 (ko) 2019-08-26
US10093722B2 (en) 2018-10-09
WO2012163810A1 (en) 2012-12-06
EP3138916B1 (en) 2019-06-19
KR20140019848A (ko) 2014-02-17
FI3564378T3 (fi) 2024-01-18
PL2714911T3 (pl) 2017-05-31
HUE037126T2 (hu) 2018-08-28
SI3138916T1 (sl) 2019-08-30
US9644024B2 (en) 2017-05-09
US10377816B2 (en) 2019-08-13
US9290565B2 (en) 2016-03-22
US20140178424A1 (en) 2014-06-26
LT2714911T (lt) 2017-02-10
CN103732750A (zh) 2014-04-16
JP2014522238A (ja) 2014-09-04
CA2837395C (en) 2021-05-18

Similar Documents

Publication Publication Date Title
GB201003924D0 (en) Immunogenic composition
ZA201503927B (en) Immunogenic composition
SG11201404447WA (en) Immunogenic composition
SI3564378T1 (sl) Imunogena sestava
ZA201308399B (en) Improved composition
IL238079A0 (en) Immunogenic preparation
SG10201702685WA (en) Immunogenic composition
GB201223342D0 (en) Immunogenic composition
GB201218660D0 (en) Immunogenic composition
EP2711011A4 (en) COMPOSITION CONTAINING PANAXADIOL
GB201115211D0 (en) Composition
LT2726579T (lt) Kompozicija
GB201116416D0 (en) Composition
GB201204968D0 (en) Immunogenic composition
GB201204851D0 (en) Immunogenic composition
GB201003918D0 (en) Immunogenic composition
GB201103037D0 (en) Composition
GB201100037D0 (en) Composition